Conference Proceedings
Australian streptokinase trial: Progress report
GA Donnan, SM Davis, BR Chambers, P Gates, E StewartWynne, D Rosen, RR Tuck, JJ McNeil, GJ Hankey, T Yamaguchi (ed.), E Mori (ed.), K Minematsu (ed.), GJ delZoppo (ed.)
THROMBOLYTIC THERAPY IN ACUTE ISCHEMIC STROKE III | SPRINGER-VERLAG | Published : 1995
Abstract
The Australian Streptokinase Trial (ASK) Study was begun in June 1992 as an Australia-wide effort to assess the efficacy of intravenous streptokinase as a thrombolytic agent to minimize morbidity and mortality after acute ischemic stroke. The study was preceded by a pilot study of 52 patients among seven centers to assess the practicality of administering an agent within a 4-h time window in Australian hospitals. The results of the pilot study suggested that a major study was practical and that a thrombolytic agent administered acutely to patients with ischemic stroke was safe.